NCT01365000View on ClinicalTrials.gov

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Healthy

Interventions

DRUG

NKTR118 Formulation 1

Oral dose, 25 mg

DRUG

NKTR118 Formulation 2

Oral dose, 25 mg

DRUG

NKTR118 Formulation 3

Oral dose, 25 mg

DRUG

NKTR118 Formulation 1a

Oral dose, 25 mg

DRUG

NKTR118 Formulation 3a

Oral dose, 25 mg

Trial Locations (1)

Unknown

Research Site, Overland Park

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY